https://ir.fibrobiologics.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_14a954ff2903678ce9699bf59a0e1fd9/fibrobiologics/files/theme/images/logo-sm.png Equisolve Investor Relations Suite https://ir.fibrobiologics.com/news-events/press-releases/detail/123/fibrobiologics-receives-notice-of-allowance-for-u-s-patent-covering-topical-fibroblast-spheroid-therapy-for-wound-healing Mon, 22 Jun 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/123/fibrobiologics-receives-notice-of-allowance-for-u-s-patent-covering-topical-fibroblast-spheroid-therapy-for-wound-healing https://ir.fibrobiologics.com/news-events/press-releases/detail/122/fibrobiologics-advances-patient-dosing-for-phase-12-clinical-trial-of-cywc628-for-the-treatment-of-diabetic-foot-ulcers Tue, 16 Jun 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/122/fibrobiologics-advances-patient-dosing-for-phase-12-clinical-trial-of-cywc628-for-the-treatment-of-diabetic-foot-ulcers https://ir.fibrobiologics.com/news-events/press-releases/detail/121/fibrobiologics-announces-first-patients-dosed-in-phase-12-clinical-trial-evaluating-cywc628-for-the-treatment-of-diabetic-foot-ulcers Wed, 03 Jun 26 07:00:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/121/fibrobiologics-announces-first-patients-dosed-in-phase-12-clinical-trial-evaluating-cywc628-for-the-treatment-of-diabetic-foot-ulcers https://ir.fibrobiologics.com/news-events/press-releases/detail/120/fibrobiologics-presents-preclinical-data-demonstrating-durable-immunomodulation-in-psoriasis-at-the-society-for-investigative-dermatology-2026-annual-meeting Fri, 22 May 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/120/fibrobiologics-presents-preclinical-data-demonstrating-durable-immunomodulation-in-psoriasis-at-the-society-for-investigative-dermatology-2026-annual-meeting https://ir.fibrobiologics.com/news-events/press-releases/detail/119/fibrobiologics-files-patent-application-for-oral-administration-of-fibroblast-therapeutics Mon, 18 May 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/119/fibrobiologics-files-patent-application-for-oral-administration-of-fibroblast-therapeutics https://ir.fibrobiologics.com/news-events/press-releases/detail/118/fibrobiologics-advancing-development-of-a-fibroblast-treatment-for-hantavirus Mon, 11 May 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/118/fibrobiologics-advancing-development-of-a-fibroblast-treatment-for-hantavirus https://ir.fibrobiologics.com/news-events/press-releases/detail/117/fibrobiologics-ceo-issues-letter-to-shareholders Tue, 05 May 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/117/fibrobiologics-ceo-issues-letter-to-shareholders https://ir.fibrobiologics.com/news-events/press-releases/detail/116/fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce-scarring Mon, 04 May 26 16:01:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/116/fibrobiologics-reports-preclinical-data-showing-fibroblast-spheroids-may-actively-reprogram-the-burn-wound-environment-to-drive-healing-and-reduce-scarring https://ir.fibrobiologics.com/news-events/press-releases/detail/115/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-12-diabetic-foot-ulcer-clinical-trial Mon, 04 May 26 08:30:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/115/fibrobiologics-announces-release-of-cywc628-drug-product-for-phase-12-diabetic-foot-ulcer-clinical-trial https://ir.fibrobiologics.com/news-events/press-releases/detail/114/fibrobiologicsreportsq1-2026-financial-resultsand-provides-corporate-update Thu, 30 Apr 26 17:55:00 -0400 https://ir.fibrobiologics.com/news-events/press-releases/detail/114/fibrobiologicsreportsq1-2026-financial-resultsand-provides-corporate-update